Ken Griffin Cognition Therapeutics Inc Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 26,950 shares of CGTX stock, worth $14,822. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,950Holding current value
$14,822% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CGTX
# of Institutions
48Shares Held
7.6MCall Options Held
0Put Options Held
0-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$1.21 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.15MShares$631,1540.0% of portfolio
-
Awm Investment Company, Inc. New York, NY650KShares$357,5000.17% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$275,0000.01% of portfolio
-
Geode Capital Management, LLC Boston, MA324KShares$178,0030.0% of portfolio
About COGNITION THERAPEUTICS INC
- Ticker CGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,710,700
- Market Cap $12.5M
- Description
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...